SEC Filing Summary: Synta Pharmaceuticals Corp. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Synta Pharmaceuticals Corp. on July 21, 2011, reporting events occurring on July 15, 2011. The filing concerns a material definitive agreement regarding a collaboration with F. Hoffmann-La Roche Ltd and its affiliate, Hoffmann-La Roche Inc. (collectively, "Roche").
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the amendment of a contractual agreement rather than financial performance results.
Material Changes and Agreement Details
On July 15, 2011, Synta and Roche executed a third amendment to their Collaboration and License Agreement, originally dated December 23, 2008. Key terms of the amendment include:
- Effective Date: June 30, 2011.
- Extension of License: The amendment extends the research license, permitting Roche to continue research on certain specified compounds targeting calcium release-activated calcium modulator channels.
- Duration: The license extends from June 30, 2011, through the term of the Agreement, which continues until the expiration of Roche's royalty obligations to Synta for all licensed products.
- Background: The initial research term ended on December 31, 2010. A second amendment in February 2011 had previously extended the license to June 30, 2011.
Guidance, Risks, and Unusual Items
The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard incorporation by reference of the amendment. The filing notes that certain portions of the amendment have been redacted and filed separately with the SEC pursuant to a request for confidential treatment.
Investor Verification Checklist
- Verify the specific compounds covered under the extended research license by reviewing the full text of Exhibit 10.1.
- Confirm the timeline for Roche's royalty obligations to determine the ultimate expiration date of the agreement.
- Review the confidential portions of the amendment filed separately with the SEC to understand any undisclosed financial terms or restrictions.
- Assess the impact of this extension on Synta's future revenue streams from royalty payments versus upfront or milestone payments.